Akums Gets Fixed Drug Combination Approval From DCGI For Erectile Dysfunction
Akums Drugs and Pharmaceuticals, an Indian contract drug manufacturing firm has introduced a Tamsulosin + Tadalafil Capsule, a fixed-dose combination of the two drugs within a hard gelatin capsule, the company said in a statement on Friday. Akums stated that it has secured approval for the drug from the Drug Controller General of India (DCGI).
Tamsulosin is primarily used when an enlarged prostate impedes normal urine flow and bladder emptying. Conversely, Tadalafil's mechanism of action supports the development of a naturally induced erection, contingent upon sexual stimulation.
Sanjeev Jain, Joint MD, Akums Drugs & Pharmaceuticals said, "The introduction of the Tamsulosin + Tadalafil Capsule underscores Akums' commitment to advancing healthcare solutions for patients grappling with benign prostatic hyperplasia and erectile dysfunction. This innovative combination therapy not only offers a more convenient treatment option but also represents a significant leap forward in our pursuit of enhancing patient outcomes."
"Our dedicated team's relentless efforts have culminated in the development of a product that not only meets rigorous regulatory standards but also aims to significantly improve the quality of life for patients. The Tamsulosin + Tadalafil Capsule stands as a testament to Akums' dedication to innovation and our commitment to elevating healthcare standards”, he added.
The company in its statement further said that in the urology segment, the fixed-dose combination offers a range of significant attributes. "It delivers substantial enhancements in both the BPH (Benign Prostatic Hyperplasia) and Erectile Dysfunction Index, leading to a significant improvement in the International Prostate Symptom Score (IPSS) across Total, Voiding, and Storage categories. This combination therapy proves to be highly effective in alleviating Lower Urinary Tract Symptoms (LUTS)," the company stated.
